相关实验视频

Updated: Sep 15, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

用于免疫治疗的PD-L1临床评估的小分子抑制剂的表征

Alicja Slota^1,2, Katarzyna Golebiowska-Mendroch^1,2, Justyna Kocik-Krol¹

¹Jagiellonian University, Faculty of Chemistry, Department of Organic Chemistry, Gronostajowa 2, 30-387 Krakow, Poland.

ACS medicinal chemistry letters

|July 16, 2025

概括

针对PD-1/PD-L1免疫检查点的三种小分子抑制剂显示,癌细胞免疫逃逸的强烈破坏. 这些化合物激活T细胞,为各种癌症的抗体疗法提供了有希望的替代方案.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

瘤利用PD-1/PD-L1免疫检查点来逃避免疫监测.
癌症免疫疗法旨在重新激活免疫系统对抗癌细胞.

研究的目的:

描述PD-L1的三个小分子抑制剂:埃维沙波丁,MAX-10181和INCB086550.
评估它们作为癌症免疫疗法的潜力.

主要方法:

一致的时间解析光 (HTRF) 试验来测量PD-1/PD-L1结合中断.
核磁共振 (NMR) 和X射线晶体学以阐明结合相互作用.
细胞测试以评估T细胞激活和细胞毒性.

主要成果:

这三种化合物都强烈抑制了人体PD-1/PD-L1与纳米分子IC50值的结合.
核磁共振和晶体学揭示了抑制剂诱导的PD-L1寡合化和稳定相互作用.
细胞测试表明剂量依赖的T细胞激活和细胞毒性.

结论:

小分子PD-L1抑制剂有效地破坏PD-1/PD-L1轴.
这些化合物具有免疫调节潜力和细胞毒性.
小分子抑制剂在癌症治疗中代表了基于抗体的疗法有前途的替代品.

关键词:

在PD-L1中.癌症免疫疗法免疫疗法临床试验是指临床试验中的临床试验.小分子抑制剂小分子抑制剂

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.